Literature DB >> 11282188

Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.

M A Stanley1, R A Moore, P K Nicholls, E B Santos, L Thomsen, N Parry, S Walcott, G Gough.   

Abstract

Protection against viral challenge with canine oral papillomavirus (COPV) was achieved by immunisation via particle-mediated DNA delivery (PMDD) of a plasmid encoding the COPV L1 gene to cutaneous and oral mucosal sites in beagle dogs. The initial dose of approximately 9 microg of DNA was followed by two booster doses at 6 week intervals. A similar approach was used to vaccinate a control group of animals with plasmid DNA encoding the Hepatitis B virus S gene. Following challenge at the oral mucosa with COPV all animals vaccinated with the COPV L1 gene were protected against disease. However five of six animals in the control group developed COPV induced papillomas at the oral mucosa. Both cell-mediated lymphoproliferative and humoral antibody responses to the DNA vaccine were observed. Our data indicate that PMDD of plasmid DNA can protect against mucosal challenge with papillomavirus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282188     DOI: 10.1016/s0264-410x(00)00533-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Epithelial cell responses to infection with human papillomavirus.

Authors:  Margaret A Stanley
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 4.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

5.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.

Authors:  Jiafen Hu; Ricai Han; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.

Authors:  Jingang Wang; Dan Zhou; Anjali Prabhu; Richard Schlegel; Hang Yuan
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

8.  Life cycle heterogeneity in animal models of human papillomavirus-associated disease.

Authors:  Woei Ling Peh; Kate Middleton; Neil Christensen; Philip Nicholls; Kiyofumi Egawa; Karl Sotlar; Janet Brandsma; Alan Percival; Jon Lewis; Wen Jun Liu; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Authors:  Hee-Jung Lee; Yoon-Ki Hur; Youn-Dong Cho; Mi-Gyeong Kim; Hoon-Taek Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

10.  The biology of papillomavirus latency.

Authors:  Gareth Adam Maglennon; John Doorbar
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.